# A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma

> **NCT02340975** · PHASE1,PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 114 (actual)

## Conditions studied

- Gastric or Gastroesophageal Junction Adenocarcinoma

## Interventions

- **BIOLOGICAL:** MEDI4736 + tremelimumab
- **BIOLOGICAL:** MEDI4736 + tremelimumab
- **BIOLOGICAL:** MEDI4736
- **BIOLOGICAL:** Tremelimumab
- **BIOLOGICAL:** MEDI4736+tremelimumab
- **BIOLOGICAL:** MEDI4736 + tremelimumab

## Key facts

- **NCT ID:** NCT02340975
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-31
- **Primary completion:** 2019-04-29
- **Final completion:** 2019-04-29
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2020-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02340975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02340975, "A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02340975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*